Chung-Yu Chen
Overview
Explore the profile of Chung-Yu Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
241
Citations
1467
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu S, Lin S, Lo H, Tang S, Hsu Y, Peng Y, et al.
Small
. 2025 Mar;
:e2412549.
PMID: 40045595
Rechargeable nickel-ion batteries (RNiBs) have attracted significant attention because of their high volumetric density, low cost, environmental friendliness, and easy recyclability. In this study, a rechargeable nickel-iodine battery using a...
2.
Hung H, Hung W, Gu Y, Chen C
Biomedicines
. 2025 Jan;
13(1).
PMID: 39857639
Glecaprevir/pibrentasvir (G/P) and elbasvir/grazoprevir (EBR/GZR) are effective treatments for chronic hepatitis C (CHC), especially in patients with chronic kidney disease (CKD). However, both regimens carry a risk of drug-induced liver...
3.
Kuo J, Chang C, Chang S, Wei Y, Chen C
Curr Oncol
. 2025 Jan;
32(1).
PMID: 39851952
Background: Afatinib and Osimertinib are first-line treatments for EGFR-mutated advanced non-small cell lung cancer (NSCLC), but their comparative efficacies and the patient groups that benefit the most remain unclear. This...
4.
Chang Y, Lin C, Hsu J, Liao S, Yu C, Peng H, et al.
JMIR Hum Factors
. 2025 Jan;
12:e53456.
PMID: 39838732
Background: Telemedicine has been utilized in the care of patients with COVID-19, allowing real-time remote monitoring of vital signs. This technology reduces the risk of transmission while providing high-quality care...
5.
Cheng S, Lin S, Peng C, Chan M, Shen S, Kuo P, et al.
Ther Adv Respir Dis
. 2025 Jan;
19:17534666241308406.
PMID: 39829048
Background: REMIT is the first real-world study of mepolizumab effectiveness in patients with severe asthma (SA) in Taiwan. Objectives: The primary objective evaluated changes in clinically significant exacerbations (CSEs; defined...
6.
Usama M, Hsu Y, Safaei M, Chen C, Han K, Ho Y, et al.
Cancer Lett
. 2025 Jan;
611():217453.
PMID: 39798832
Although breast cancer treatment has evolved significantly in recent years, drug resistance remains a major challenge. To identify new targets for breast cancer, we found that stage-specific embryonic antigen 4...
7.
Kuo J, Jian M, Chiang C, Kuo W, Lin I, Kuo Y, et al.
Biosens Bioelectron
. 2024 Dec;
271:117074.
PMID: 39718483
The EZ DEVICE is an integrated fluorescence microflow cytometer designed for automated cell phenotyping and enumeration using artificial intelligence (AI). The platform consists of a laser diode, optical filter, objective...
8.
Su C, Chen C, Liu C, Yang Y, Wu P
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682184
Background: Everolimus is approved for treating breast, renal, and pancreatic neuroendocrine cancers but carries the risk of hepatitis B virus (HBV) reactivation (HBVr) and hepatitis. However, data on HBVr in...
9.
Po H, Chu Y, Tsai H, Chen C, Chiu Y
J Clin Nurs
. 2024 Nov;
PMID: 39528412
Aims And Objectives: This study aims to compare the effectiveness of the case management model and the primary nursing care model by focusing on hospital stay length, readmission, follow-up resource...
10.
Hu S, Lin T, Chen C, He Y, Huang W, Hsieh C, et al.
Pharmaceuticals (Basel)
. 2024 Oct;
17(10).
PMID: 39458997
Background: Adjuvant chemotherapy, particularly cisplatin, is recommended for non-small cell lung carcinoma (NSCLC) patients at high risk of recurrence. EF-hand domain-containing protein D2 (EFHD2) has been recently shown to increase...